These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28027910)

  • 1. Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies.
    Beerepoot P; Nazari R; Salahpour A
    Pharmacol Res; 2017 Mar; 117():242-251. PubMed ID: 28027910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaperoning G protein-coupled receptors: from cell biology to therapeutics.
    Tao YX; Conn PM
    Endocr Rev; 2014 Aug; 35(4):602-47. PubMed ID: 24661201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular chaperones and G protein-coupled receptor maturation and pharmacology.
    Tao YX
    Mol Cell Endocrinol; 2020 Jul; 511():110862. PubMed ID: 32389798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific ligands as pharmacological chaperones: The transport of misfolded G-protein coupled receptors to the cell surface.
    Nakamura M; Yasuda D; Hirota N; Shimizu T
    IUBMB Life; 2010 Jun; 62(6):453-9. PubMed ID: 20503438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening methods for identifying pharmacological chaperones.
    Shin MH; Lim HS
    Mol Biosyst; 2017 Mar; 13(4):638-647. PubMed ID: 28265599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
    Robben JH; Sze M; Knoers NV; Deen PM
    Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological chaperone action on G-protein-coupled receptors.
    Bernier V; Bichet DG; Bouvier M
    Curr Opin Pharmacol; 2004 Oct; 4(5):528-33. PubMed ID: 15351360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors.
    Hanyroup S; Anderson RC; Nataraja S; Yu HN; Millar RP; Newton CL
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34192304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of Function of Mutant Luteinising Hormone Receptors with Deficiencies in Cell Surface Expression, Hormone Binding, and Hormone Signalling.
    Newton CL; Anderson RC; Kreuchwig A; Krause G; Katz AA; Millar RP
    Neuroendocrinology; 2021; 111(5):451-464. PubMed ID: 32316022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Rescue of Inactivating Mutations of the Human Neurokinin 3 Receptor Using Pharmacological Chaperones.
    Anderson RC; Hanyroup S; Song YB; Mohamed-Moosa Z; van den Bout I; Schwulst AC; Kaiser UB; Millar RP; Newton CL
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of GPCR Anterograde Trafficking by Molecular Chaperones and Motifs.
    Young B; Wertman J; Dupré DJ
    Prog Mol Biol Transl Sci; 2015; 132():289-305. PubMed ID: 26055064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellularly located misfolded glycoprotein hormone receptors associate with different chaperone proteins than their cognate wild-type receptors.
    Mizrachi D; Segaloff DL
    Mol Endocrinol; 2004 Jul; 18(7):1768-77. PubMed ID: 15105436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target.
    Maya-Núñez G; Ulloa-Aguirre A; Janovick JA; Conn PM
    Subcell Biochem; 2012; 63():263-89. PubMed ID: 23161143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases.
    Aubi O; Knappskog PM; Martinez A
    Methods Mol Biol; 2019; 1873():279-292. PubMed ID: 30341617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANKRD13C acts as a molecular chaperone for G protein-coupled receptors.
    Parent A; Roy SJ; Iorio-Morin C; Lépine MC; Labrecque P; Gallant MA; Slipetz D; Parent JL
    J Biol Chem; 2010 Dec; 285(52):40838-51. PubMed ID: 20959461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using pharmacological chaperones to restore proteostasis.
    Wang YJ; Di XJ; Mu TW
    Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological chaperoning: a primer on mechanism and pharmacology.
    Leidenheimer NJ; Ryder KG
    Pharmacol Res; 2014 May; 83():10-9. PubMed ID: 24530489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases.
    Ulloa-Aguirre A; Zariñán T; Gutiérrez-Sagal R; Tao YX
    Front Endocrinol (Lausanne); 2022; 13():934685. PubMed ID: 36093106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Kikume green-red fusions to study the influence of pharmacological chaperones on trafficking of G protein-coupled receptors.
    Ridelis I; Schmidt A; Teichmann A; Furkert J; Wiesner B; Schülein R
    FEBS Lett; 2012 Mar; 586(6):784-91. PubMed ID: 22306118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.